Investing.com - Spero Therapeutics (NASDAQ: SPRO) reported second quarter EPS of $-0.330, $0.05 better than the analyst estimate of $-0.380. Revenue for the quarter came in at $10.2M versus the consensus estimate of $4.9M.
Spero Therapeutics's stock price closed at $1.34. It is down -20.710% in the last 3 months and down -11.920% in the last 12 months.
Spero Therapeutics saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Spero Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Spero Therapeutics's Financial Health score is "great performance".
Check out Spero Therapeutics's recent earnings performance, and Spero Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar